Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Madrid – page 271

3 294 clinical trials in Madrid, Spain across 24 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Madrid at a glance
3 294
clinical trials
  • Research sites24
Type of trial
Recruitment status
Quick filters

3 294 trials in Madrid

Open in trial search

Dry eye

Not recruiting

Study on the Effectiveness and Safety of Insulin, Ciclosporin, and Benzalkonium Chloride in Patients with Moderate to Severe Dry Eye Disease

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ciclosporin
  • Sponsor:Hospital Clinico San Carlos

Liver disorder

Not recruiting

Study on Zinc Acexamate for Patients with Advanced Chronic Liver Disease

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Zinc Acexamate
  • Sponsor:Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

Study on Golexanolone for Patients with Primary Biliary Cholangitis Experiencing Fatigue and Cognitive Dysfunction

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Golexanolone
  • Sponsor:Umecrine Cognition AB

Breast cancer+2

Not recruiting

Study of Durvalumab, Olaparib, and Fulvestrant for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer with Specific Genetic Alterations

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Unicancer

Chondrosarcoma

Not recruiting

Study of INBRX-109 (ozekibart) compared to placebo in adults with unresectable or metastatic chondrosarcoma - a rare bone cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acetylcysteine
  • Sponsor:Inhibrx Biosciences Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Lenalidomide, Bortezomib, Dexamethasone, Isatuximab, and Iberdomide for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Bortezomib
  • Sponsor:Fundacion PETHEMA

Study on Talazoparib and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Neoplasm

Not recruiting

Study on the Safety of Avelumab for Patients with Solid Tumors Continuing Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Merck KGaA

Study on the Safety and Effectiveness of Luveltamab Tazevibulin (STRO-002) for Infants and Children Under 12 with Acute Myeloid Leukemia (AML)

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Stro-002
  • Sponsor:Sutro Biopharma Inc.

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Frexalimab and Teriflunomide in Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Hodgkin's disease+6

Not recruiting

Study of Cobolimab and Dostarlimab for Children and Young Adults with Newly Diagnosed or Relapsed/Refractory Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Cobolimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study of Retifanlimab, INCAGN02385, and INCAGN02390 for First-Line Treatment in Patients with PD-L1 Positive Recurrent/Metastatic Head and Neck Cancer

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Retifanlimab
  • Sponsor:Incyte Biosciences International S.a.r.l.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Madrid

What the registry says about research in the country

01 Autoimmune and Inflammatory Conditions

Investigating novel treatments for cutaneous lupus erythematosus and immune thrombocytopenia, with studies evaluating new therapeutic approaches to manage these challenging conditions.

  • Lupus skin manifestations
  • Platelet disorders
  • Immune system regulation

Research focuses on improving treatment outcomes and quality of life for patients with autoimmune disorders.

02 Metabolic and Endocrine Disorders

Clinical trials examining innovative therapies for Type 1 Diabetes in combination with weight management, targeting both glycemic control and obesity-related complications.

  • Diabetes management
  • Weight control
  • Metabolic health

Studies aim to develop comprehensive treatment approaches for complex metabolic conditions.

03 Neurological Conditions

Breakthrough research in multiple sclerosis and acute ischemic stroke, exploring new therapeutic options for both pediatric and adult populations.

  • MS treatment in young patients
  • Stroke intervention
  • Neurological recovery

Focus on developing targeted treatments to improve neurological outcomes and patient care.

04 Infectious Disease Prevention

Comprehensive vaccine studies targeting respiratory syncytial virus, influenza, and herpes zoster, with particular attention to vulnerable populations.

  • Vaccine development
  • Immune response
  • Prevention strategies

Research aims to enhance protection against common and serious infectious diseases.

05 Oncology Research

Innovative studies in mantle cell lymphoma and bladder cancer, exploring combination therapies and targeted treatments to improve patient outcomes.

  • Lymphoma treatment
  • Bladder cancer therapy
  • Immunotherapy approaches

Focus on developing more effective and personalized cancer treatments.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.